Lupin’s subsidiary -- Lupin Pharmaceuticals Inc is recalling an unspecified number of penicillamine tablets in the US. The medication is used to treat rheumatoid arthritis and Wilson’s disease. Baltimore-based Lupin Pharmaceuticals Inc is recalling the affected lot that was produced at the drugmaker’s Nagpur-based facility. As per the US Food and Drug Administration (USFDA), the company is recalling the affected lot due to ‘failed dissolution specifications’. The company initiated the Class II nationwide (US) voluntary recall on November 22.
As per the USFDA, a class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The Indian pharmaceutical industry is the third largest in the world by volume. The US is the world’s largest market for pharmaceutical products.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
